NCT05790941招募中1 期
Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Target Area Hair Count
研究概览
简要总结
Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.
详细描述
A Single-Blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Unlabeled bottle.
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects, age 22 to 65 years, in general good health.
- •Patients with diagnosed hypotrichosis of the eyebrows.
- •Subjects with active hair loss within the last 12 months.
- •Patients willing to refrain from initiation of any new vitamins or nutritional supplements for the duration of the study.
- •Patients willing to refrain from use of any hair growth therapies (oral or topical) other than the investigational product.
排除标准
- •Subjects with an active disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp that may interfere with the assessment of scalp skin health in the treated regions.
- •History of hair transplants, scalp reduction, current hair weave or tattooing in the target area, artificial hair coloring two months prior to initiation of study which makes it difficult to perform hair count assessment.
- •Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a time period.
- •Subjects with a history of chemotherapy, receiving cytotoxic agents, radiation, or laser/surgical therapy of the scalp within the past 12 months.
- •Any known or underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
- •Subjects with clinical diagnosis of hair loss other than hypotrichosis of the eyebrows.
- •Subjects with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.
- •Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test articles.
- •Pregnant or lactating females or planning to become pregnant for the duration of the study.
- •Subjects using medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
- •Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.
- •Current or recent (2 months) history of severe diet or eating disorder.
研究组 & 干预措施
Topical Latanoprost/Minoxidil formulation
Experimental
8 participants: Topical Latanoprost/Minoxidil formulation applied to both eyebrows once a day for 90 days
干预措施: Latanoprost and Minoxidil (Combination Product)
Control Group
Placebo Comparator
4 participants: Vehicle applied to both eyebrows once a day for 90 days
干预措施: Latanoprost and Minoxidil (Combination Product)
结局指标
主要结局
Target Area Hair Count
时间窗: 90 days
Target Area Hair Count as Determined by the Brigham Tool for Alopecia
次要结局
- Standardized Global Photographs(90 days)
- Change in Total Area Hair Darkness(90 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Latanoprost for the Treatment of Menière's DiseaseMenière's DiseaseNCT01973114Synphora AB100
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair LossAndrogenetic AlopeciaNCT00151515Johnson & Johnson Consumer and Personal Products Worldwide352
招募中
早期 1 期
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Endocrine Therapy-Induced AlopeciaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8NCT05417308Ohio State University Comprehensive Cancer Center50
已完成
2 期
Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X SyndromeFragile X SyndromeNCT02680379Université de Sherbrooke22
已完成
4 期
Efficacy and Tolerability of an Innovative Formulation of BAK-free LatanoprostPrimary Open-angle GlaucomaNCT03331770Laboratorios Poen103